GURU.Markets stock price, segment price, and overall market index valuation
The company's share price AC Immune
AC Immune is a Swiss biotech company specializing in the treatment of neurodegenerative diseases such as Alzheimer's. Its share price reflects a long and arduous history of clinical trials in this highly complex area of medicine.
Share prices of companies in the market segment - Neuro
AC Immune (ACIU) is a Swiss biopharmaceutical company specializing in the development of vaccines, antibodies, and diagnostics for the treatment of neurodegenerative diseases such as Alzheimer's. We classify it under the "Neurology" category. The chart below illustrates the dynamics of this complex biotech sector.
Broad Market Index - GURU.Markets
AC Immune is a Swiss biotech company specializing in developing vaccines and treatments for neurodegenerative diseases, such as Alzheimer's. Its focus on this topic makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how AC Immune compares to it.
Change in the price of a company, segment, and market as a whole per day
ACIU - Daily change in the company's share price AC Immune
Shares of AC Immune, a Swiss biotech company focused on Alzheimer's disease, are extremely volatile. Change_co measures the market reaction to clinical trial data. This metric is an indispensable component for building valuation models for companies in this complex field on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
AC Immune SA is a biotech company. This chart highlights the sector's extreme volatility. Comparison with ACIU, which focuses on neurodegenerative diseases, helps assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
AC Immune is a Swiss biopharmaceutical company specializing in drugs for the treatment of neurodegenerative diseases such as Alzheimer's. This is one of the most complex and risky areas in biotech. The chart below illustrates the high volatility typical of this sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization AC Immune
AC Immune SA's year-to-date performance is a story of its long-standing battle against neurodegenerative diseases like Alzheimer's. Its 12-month market cap depends entirely on the results of clinical trials of its vaccines and antibodies. Any positive news could trigger a sharp rise, as the company operates in one of the most complex, yet largest, markets.
Annual dynamics of market capitalization of the market segment - Neuro
AC Immune SA is a Swiss clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases such as Alzheimer's. Its stock performance is entirely dependent on clinical trial results, reflecting its enormous potential and high risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
AC Immune is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials for neurodegenerative diseases. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization AC Immune
The market capitalization of AC Immune, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its drugs and vaccines for the treatment of neurodegenerative diseases, such as Alzheimer's.
Monthly dynamics of market capitalization of the market segment - Neuro
AC Immune is a Swiss biotech company pioneering the development of immunotherapy treatments for neurodegenerative diseases such as Alzheimer's. The chart below reflects investor sentiment in the neuroscience sector, where the need for a breakthrough is particularly high.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
AC Immune SA is a Swiss biotech company focused on treating neurodegenerative diseases such as Alzheimer's. Its shares are highly volatile, driven by clinical trial results. This is a classic biotech story, unrelated to broader market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization AC Immune
Shares of AC Immune, a Swiss company fighting neurodegenerative diseases, are extremely volatile. Weekly price movements depend entirely on the results of clinical trials of drugs for Alzheimer's and Parkinson's diseases. The chart below visualizes how hopes and disappointments in this complex field of medicine influence the stock's price.
Weekly dynamics of market capitalization of the market segment - Neuro
How unique is AC Immune's performance in the biotech sector? This chart compares the weekly fluctuations of the Alzheimer's disease company's stock against the overall trend. This helps us understand whether its sharp movements are a unique reaction to news in this complex field or reflect broader sentiment across the sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
AC Immune is a Swiss biotech company focused on fighting Alzheimer's disease. This chart shows how out of sync its weekly performance is with the broader market. Its stock price movements are 100% driven by news about its high-stakes clinical trials.
Market capitalization of the company, segment and market as a whole
ACIU - Market capitalization of the company AC Immune
AC Immune SA's valuation on the chart reflects its long-standing efforts to develop drugs and vaccines for neurodegenerative diseases, primarily Alzheimer's. The company's market cap is extremely sensitive to clinical trial results. The dynamics illustrate the complex and risky path to combating one of the most complex diseases.
ACIU - Share of the company's market capitalization AC Immune within the market segment - Neuro
AC Immune SA is a Swiss biotechnology company whose market share is based on its focus on developing vaccines and antibodies for the treatment of neurodegenerative diseases such as Alzheimer's disease.
Market capitalization of the market segment - Neuro
The chart below is a barometer of the biotech sector fighting Alzheimer's disease. AC Immune is a leading developer of vaccines and antibodies. The dynamics on the chart reflect the enormous risks and hopes associated with finding a cure for one of the most dreaded diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart represents the market valuation of the fight against Alzheimer's disease. AC Immune's market capitalization reflects investors' faith in its scientific approaches aimed at diagnosing and treating neurodegenerative diseases. The line shows how hope for defeating one of the main threats to aging shapes its share of the global economy.
Book value capitalization of the company, segment and market as a whole
ACIU - Book value capitalization of the company AC Immune
AC Immune SA's book value reflects its research capital, which is focused on combating neurodegenerative diseases. The chart below reflects the value of its pipeline of vaccines and antibodies against Alzheimer's and Parkinson's diseases. A rising line indicates success in clinical trials.
ACIU - Share of the company's book capitalization AC Immune within the market segment - Neuro
For AC Immune, a biopharmaceutical company focused on neurodegenerative diseases, its tangible assets are its cutting-edge laboratories and scientific equipment. The chart shows the company's share of this highly specialized scientific infrastructure, which forms the physical basis for the fight against Alzheimer's disease.
Market segment balance sheet capitalization - Neuro
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, AC Immune, which develops therapies for neurodegenerative diseases, looks like a "light" stock. Its value lies in its patents and scientific data, not in its large manufacturing plants. Its business is science, not mass production.
Book value of all companies included in the broad market index - GURU.Markets
AC Immune is a Swiss biotech company focused on fighting neurodegenerative diseases such as Alzheimer's. Its assets include patents, scientific platforms, and research data. The company's balance sheet is a capitalized hope for defeating one of the most complex diseases affecting millions.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - AC Immune
AC Immune's balance sheet is its cash and scientific platform. Its market cap is a bet on a breakthrough in Alzheimer's treatment. The MvsBCap_Co chart shows how the market views the chances of success in the most complex and risky area of biotech.
Market to book capitalization ratio in a market segment - Neuro
AC Immune is a Swiss biotech company specializing in developing treatments for neurodegenerative diseases such as Alzheimer's. The chart shows the high speculative valuation of its scientific approach and investors' hopes for a breakthrough in this complex field of medicine.
Market to book capitalization ratio for the market as a whole
AC Immune is a Swiss biotech company specializing in developing vaccines and therapeutics for neurodegenerative diseases such as Alzheimer's. Its value lies in its scientific platform. This chart illustrates why investors are willing to pay a premium for innovative approaches to treating complex diseases.
Debts of the company, segment and market as a whole
ACIU - Company debts AC Immune
AC Immune, a biopharmaceutical company focused on neurodegenerative diseases like Alzheimer's, uses debt to finance its complex scientific work. This chart shows how the company raises capital to conduct lengthy and expensive clinical trials of vaccines and antibodies. Debt here represents the hope of a breakthrough in treatment.
Market segment debts - Neuro
AC Immune is a Swiss biotech company specializing in developing vaccines and therapies for the treatment of neurodegenerative diseases, primarily Alzheimer's disease. This is one of the most complex and risky areas in pharmaceuticals. This chart shows how the company funds its multi-year and very expensive clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio AC Immune
AC Immune is a Swiss biotech company focused on fighting neurodegenerative diseases such as Alzheimer's. This chart shows its dependence on external funding. In a field where decades of research can yield no results, high debt is an extreme risk that can only be justified by a scientific breakthrough.
Market segment debt to market segment book capitalization - Neuro
AC Immune is a Swiss biotech company focused on developing vaccines and diagnostic tests for neurodegenerative diseases such as Alzheimer's. This is one of the most complex areas in medicine. The chart shows how the company's debt load relates to the risks and market capitalization of the entire biotech sector.
Debt to book value of all companies in the market
AC Immune (ACIU) is a Swiss biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer's. This chart shows the overall debt burden of the economy. It helps explain why ACIU, at the forefront of science, is funded by investors rather than creditors, proving the effectiveness of its developments.
P/E of the company, segment and market as a whole
P/E - AC Immune
This chart for the Swiss company AC Immune, developing treatments for neurodegenerative diseases such as Alzheimer's, is a measure of hope. There is no P/E ratio. The company's valuation is a bet on a breakthrough in one of the most complex areas of medicine. The chart is extremely sensitive to news of clinical trial results.
P/E of the market segment - Neuro
This chart illustrates the average P/E for biotech companies operating in the neuroscience field. For AC Immune, which focuses on Alzheimer's disease, it serves as a backdrop. It highlights the overall level of hope and disappointment in this highly complex area of medicine, providing context for assessing the risks associated with AC Immune.
P/E of the market as a whole
AC Immune is a Swiss biopharmaceutical company specializing in the development of vaccines and therapeutics for the treatment of neurodegenerative diseases, such as Alzheimer's. The company is working on one of the most complex problems in medicine. This chart, reflecting risk appetite, helps understand how investors view this area.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company AC Immune
AC Immune is a Swiss biotech company focused on developing vaccines and therapeutics to combat neurodegenerative diseases, such as Alzheimer's, by targeting abnormal proteins. This graph reflects expectations for a breakthrough in this complex area of medicine. Estimates are dependent on clinical trial results.
%20P%2FE%20AC%20Immune&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-AC-Immune&v=1772615200087 "Chart of the company's future (projected) P/E AC Immune")
Future (projected) P/E of the market segment - Neuro
AC Immune is a Swiss biotech company specializing in developing vaccines and therapies for neurodegenerative diseases, primarily Alzheimer's disease. This chart reflects the company's long-term profitability expectations. It shows how the market assesses the chances of success for their risky but potentially breakthrough research.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772615200124 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
AC Immune is a Swiss biotech company focused on developing vaccines and drugs for neurodegenerative diseases such as Alzheimer's. Its future depends on scientific breakthroughs. This market expectations chart shows investor appetite for high-risk but potentially breakthrough areas of medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772615200275 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit AC Immune
AC Immune is a Swiss biotechnology company specializing in the development of vaccines and therapies for the treatment of neurodegenerative diseases, primarily Alzheimer's disease. Its financial results reflect the high costs of clinical research in one of the most complex areas of medicine.
Profit of companies in the market segment - Neuro
AC Immune is a Swiss biotech company focused on fighting neurodegenerative diseases like Alzheimer's. This is one of the most challenging areas in medicine. This chart illustrates the enormous risks and potential of CNS drug development, where failures are numerous, but a successful drug could generate billions and change lives.
Overall market profit
AC Immune is a Swiss biotech company focused on developing drugs and vaccines against neurodegenerative diseases such as Alzheimer's. Its future depends entirely on the success of clinical trials. This is a risky bet on a scientific breakthrough, one that has no direct correlation to the economic cycles visible in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company AC Immune
AC Immune is a Swiss biotech company focused on developing vaccines and therapies for neurodegenerative diseases, particularly Alzheimer's disease. This graph reflects expectations, which are entirely dependent on clinical trial results. Any breakthrough in this complex field will dramatically change the outlook.
%20profit%20of%20the%20company%20AC%20Immune&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-AC-Immune&v=1772615200405 "Graph of future (projected) profit of the company AC Immune")
Future (predicted) profit of companies in the market segment - Neuro
AC Immune is a Swiss biotechnology company focused on developing vaccines and therapeutics for neurodegenerative diseases, such as Alzheimer's. This chart shows the revenue forecast for the entire neuropharmaceutical sector. It reflects expectations for breakthroughs in this complex field, which is important for assessing AC Immune's scientific potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772615200426 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
AC Immune is a Swiss biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer's. Its success depends on scientific breakthroughs. The economic climate, reflected in the graph, influences its success through the availability of funding for long and highly risky clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772615200436 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - AC Immune
AC Immune is a Swiss clinical-stage biotech company focused on developing vaccines and antibodies for the treatment of neurodegenerative diseases, primarily Alzheimer's. This chart shows how investors view its risky but potentially highly valuable developments in one of the most complex areas of medicine.
P/S market segment - Neuro
AC Immune is a Swiss clinical-stage biotech company specializing in the development of immunotherapy-based treatments and diagnostics for neurodegenerative diseases, primarily Alzheimer's disease. This chart shows the average valuation in the sector, helping to understand how the market views AC Immune's scientific approaches to one of medicine's most complex problems.
P/S of the market as a whole
AC Immune is a Swiss biotech company specializing in developing vaccines and antibodies to treat neurodegenerative diseases, primarily Alzheimer's. This is an area with a huge need, but also a history of failure. This market valuation chart helps us understand the premium investors are paying for this potentially breakthrough, yet highly risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company AC Immune
AC Immune is a Swiss biotech company focused on treating neurodegenerative diseases such as Alzheimer's. Its valuation is entirely dependent on the success of clinical trials. This chart reflects investor expectations for a breakthrough in this complex area of medicine and future sales of its drugs.
%20P%2FS%20AC%20Immune&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-AC-Immune&v=1772615200695 "The graph of the company's future (projected) P/S AC Immune")
Future (projected) P/S of the market segment - Neuro
AC Immune is a Swiss biopharmaceutical company specializing in the development of vaccines and antibodies for the treatment of neurodegenerative diseases, such as Alzheimer's. This chart compares market expectations for its future revenue with those of other neuroscience companies. The valuation reflects the company's expectations for the success of its innovative approaches.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772615200735 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
AC Immune is a Swiss biotech company focused on fighting neurodegenerative diseases such as Alzheimer's. Its success depends on scientific breakthroughs. Market optimism, evident in this chart, is essential for attracting the investment needed for long-term, risky research in one of the most complex areas of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772615200765 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales AC Immune
AC Immune is a Swiss biotech company focused on developing vaccines and therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease. Its revenue comes from upfront and milestone payments from pharmaceutical partners. The chart shows the funding supporting its fight against these complex diseases.
Sales of companies in the market segment - Neuro
AC Immune is a Swiss biotechnology company specializing in the development of vaccines and therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease. Revenue is generated through partnerships with major pharmaceutical companies. This chart reflects the company's significant investment in Alzheimer's drug discovery, in which AC Immune is a leader.
Overall market sales
AC Immune is a Swiss biotech company focused on combating neurodegenerative diseases such as Alzheimer's. The company's prospects depend on the success of its clinical programs. The connection to this graph is indirect: the overall state of the economy influences public and private funding for research in this complex field.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company AC Immune
AC Immune is a Swiss biotech company focused on developing vaccines and therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease. This chart reflects analysts' highly speculative expectations for the success of its clinical programs in one of the most complex areas of medicine.
%20sales%20of%20the%20company%20AC%20Immune&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-AC-Immune&v=1772615200956 "Schedule of future (projected) sales of the company AC Immune")
Future (projected) sales of companies in the market segment - Neuro
AC Immune is a Swiss biotech company specializing in the development of vaccines and therapeutics for the treatment of neurodegenerative diseases, particularly Alzheimer's disease. This chart shows the outlook for the neuroscience sector, allowing one to assess the risks and potential rewards in this highly complex field of medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772615200982 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
AC Immune is a Swiss biotech company specializing in developing treatments for neurodegenerative diseases such as Alzheimer's. This chart, which reflects biotech investments, is important to the company. Drug development in this complex field requires significant capital, and economic stability supports investment in the sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772615201042 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality AC Immune
AC Immune is a Swiss biotech company at the forefront of the fight against neurodegenerative diseases such as Alzheimer's. Its activities are focused on the development of vaccines and antibodies. This chart reflects significant investments in scientific research, which forms the basis for the development of potential treatments.
Market segment marginality - Neuro
AC Immune is a Swiss biotech company focused on developing vaccines and therapeutics to combat neurodegenerative diseases, primarily Alzheimer's disease. This chart reflects their significant investment in research aimed at solving one of the most challenging medical problems of our time.
Market marginality as a whole
AC Immune is a Swiss biotech company, a pioneer in developing vaccines and antibodies for the treatment of neurodegenerative diseases such as Alzheimer's. The overall picture of profitability is irrelevant for them. Their future depends on the success of their risky but potentially breakthrough approaches in the clinic. This is a bet on solving one of the most complex problems in medicine.
Employees in the company, segment and market as a whole
Number of employees in the company AC Immune
AC Immune is a Swiss biotech company specializing in the development of vaccines and antibodies for the treatment of neurodegenerative diseases such as Alzheimer's. This graph shows the team of scientists. The size of the staff reflects the complexity and long-term nature of research in this field.
Share of the company's employees AC Immune within the market segment - Neuro
AC Immune is a Swiss biotech company, a pioneer in precision medicine for neurodegenerative diseases such as Alzheimer's. This chart shows the percentage of leading neuroscience researchers the company attracts. This demonstrates its focus on developing vaccines and diagnostics to combat these devastating illnesses.
Number of employees in the market segment - Neuro
AC Immune is a Swiss biotech company focused on developing vaccines and antibodies to treat neurodegenerative diseases such as Alzheimer's. The chart shows employment in the CNS research sector. The growing number of scientists reflects the enormous effort and investment being made to address one of the most challenging problems in modern medicine.
Number of employees in the market as a whole
AC Immune SA is a Swiss biotechnology company specializing in the development of vaccines and therapeutics to combat neurodegenerative diseases, primarily Alzheimer's disease. This graph shows overall employment, and research-intensive companies like AC Immune are at the forefront of medicine, creating jobs for the world's best scientists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company AC Immune (ACIU)
AC Immune SA is a Swiss biotech company specializing in neurodegenerative diseases such as Alzheimer's. Its value is determined by the potential of its scientific developments. This chart illustrates a model with a very high market capitalization per employee. Investors are betting that a small team of scientists can create a drug for a huge market.
%20of%20the%20company%20AC%20Immune%20(ACIU)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-AC-Immune-ACIU&v=1772615201621 "Chart of market capitalization per employee (in thousands of dollars) of the company AC Immune (ACIU)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
AC Immune is a Swiss biotech company focused on developing vaccines and therapies against neurodegenerative diseases such as Alzheimer's. This metric reflects investors' high hopes for a breakthrough in one of the most complex areas of medicine, assessing the potential of the research team per employee.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772615201653 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
AC Immune is a Swiss biotech company focused on developing vaccines and therapies against neurodegenerative diseases such as Alzheimer's. This chart shows a high market value per employee, reflecting investor hopes for a breakthrough in one of the most complex areas of medicine.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772615201673 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company AC Immune (ACIU)
AC Immune (ACIU) is a Swiss biotech company focused on developing drugs for neurodegenerative diseases (Alzheimer's, Parkinson's). This involves highly complex R&D. This chart shows the "cost" of fighting Alzheimer's—the negative profit (expense) for each scientist working on vaccines and diagnostics.
%20Chart%20AC%20Immune%20(ACIU)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-AC-Immune-ACIU&v=1772615201697 "Company Profit Per Employee (in thousands of dollars) Chart AC Immune (ACIU)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
AC Immune is a Swiss biotech company specializing in the development of vaccines and antibodies for the treatment of neurodegenerative diseases, primarily Alzheimer's. This chart shows the benchmark for personnel efficiency in biotech. It is important for assessing how effectively AC Immune's scientific team is deploying capital in this highly complex field of medicine.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772615201776 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
AC Immune is a Swiss biotech company specializing in developing treatments for neurodegenerative diseases such as Alzheimer's. This is one of the most complex areas in medicine. The chart shows the R&D investment (negative return) per employee required to find a breakthrough in treating brain diseases.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772615201853 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee AC Immune (ACIU)
AC Immune is a Swiss biotech company focused on developing vaccines and therapies against neurodegenerative diseases such as Alzheimer's. This chart reflects its scientific focus. The lack of revenue per employee is typical for a company conducting long-term and expensive research in one of the most complex areas of medicine.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-AC-Immune-ACIU&v=1772615201915 "Sales chart per company employee AC Immune (ACIU)")
Sales per employee in the market segment - Neuro
AC Immune (ACIU) is a Swiss biotech company specializing in the development of vaccines and diagnostic tests for neurodegenerative diseases, primarily Alzheimer's disease. This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their R&D platform.
Sales per employee for the market as a whole
AC Immune is a Swiss biotech company focused on developing vaccines and diagnostics for Alzheimer's disease. It is a clinical-stage R&D company. This graph (close to zero) reflects their current investment in research: the company has no stable revenue, but it has a team of scientists working on one of the most complex problems in medicine.
Short shares by company, segment and market as a whole
Shares shorted by company AC Immune (ACIU)
AC Immune is a Swiss biotech focused on developing drugs and vaccines against neurodegenerative diseases, primarily Alzheimer's. This chart shows bearish bets. The shorts are driven by the vast "Alzheimer's graveyard"—dozens of companies have failed in this field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-AC-Immune-ACIU&v=1772615202022 "Short Shares Chart for the Company AC Immune (ACIU)")
Shares shorted by market segment - Neuro
AC Immune (ACIU) is a Swiss biotech company focused on developing vaccines and diagnostics for neurodegenerative diseases, primarily Alzheimer's disease. This chart shows the bets against the entire biotech sector. The rising bets against the industry reflect deep investor skepticism about the success of Alzheimer's treatments after decades of failure.
Shares shorted by the overall market
AC Immune (ACIU) is a Swiss biotech company focused on developing drugs for neurodegenerative diseases (Alzheimer's). It's a "biotech graveyard." This market fear chart shows when investors flee the riskiest sectors. ACIU's shares, operating in a highly complex field, are falling sharply.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator AC Immune (ACIU)
AC Immune is a Swiss biotech focused on a daunting task: treating neurodegenerative diseases (such as Alzheimer's). It's a field full of failures. This chart measures the level of hope. It shows when the stock is overbought on the slightest glimmer of hope in the data or oversold on yet another dip.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-AC-Immune-ACIU&v=1772615202281 "RSI 14 indicator chart for the company's stock AC Immune (ACIU)")
RSI 14 Market Segment - Neuro
AC Immune is a Swiss biotech company specializing in the development of vaccines and antibodies for the treatment of neurodegenerative diseases, primarily Alzheimer's disease. This chart measures the collective excitement in the neuroscience biotech sector. It helps determine whether the entire segment is overheated by Alzheimer's news.
RSI 14 for the overall market
AC Immune, a biotech company, depends on this schedule. To fund expensive clinical trials, it requires a constant influx of capital. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like ACIU are forced to struggle to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ACIU (AC Immune)
AC Immune is a Swiss biotech company specializing in the development of vaccines and antibodies for the treatment of neurodegenerative diseases (Alzheimer's, Parkinson's). This chart shows the average target price. Analysts' forecasts are based on clinical data and the success of partnerships with major pharmaceutical companies.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ACIU-AC-Immune&v=1772615202643 "A chart showing analyst consensus forecasts for the expected stock price. ACIU (AC Immune)")
The difference between the consensus estimate and the actual stock price ACIU (AC Immune)
AC Immune (ACIU) is a Swiss biotech company specializing in developing vaccines and antibodies for the treatment of neurodegenerative diseases, primarily Alzheimer's. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the (high, but risky) potential analysts see in their anti-tau therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ACIU-AC-Immune&v=1772615202810 "A chart showing the difference between the consensus forecast and the actual stock price. ACIU (AC Immune)")
Analyst consensus forecast for stock prices by market segment - Neuro
AC Immune (ACIU) is a Swiss biotech company focused entirely on neurodegenerative diseases. It develops vaccines and antibodies against Alzheimer's and Parkinson's diseases. This chart shows general expectations for the neuroscience sector, reflecting whether experts believe a long-awaited breakthrough in Alzheimer's treatment is possible.
Analysts' consensus forecast for the overall market share price
AC Immune is a Swiss biotech company specializing in developing vaccines and treatments for neurodegenerative diseases, primarily Alzheimer's. This chart shows the overall "risk appetite." For AC Immune, which is working on the "holy grail" of neuroscience, overall market optimism (a rising chart) is critical to funding very expensive and time-consuming research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index AC Immune
AC Immune (ACIU) is a Swiss biotech company focused entirely on the battle against neurodegenerative diseases (Alzheimer's, Parkinson's). They are developing vaccines and antibodies against harmful proteins (tau, alpha-synuclein). This chart is a clear indicator of faith in their R&D. It reflects their progress in this most challenging valley of death for pharmaceutical development.
AKIMA Market Segment Index - Neuro
AC Immune is a Swiss biotech company specializing in developing treatments for neurodegenerative diseases, primarily Alzheimer's disease. This chart shows the average index for the neurosegment. It provides investors with a benchmark for how AC Immune's performance compares to the sector average for companies working on this complex problem.
The AKIM Index for the overall market
AC Immune is a Swiss biopharmaceutical company focused on diagnosing and treating neurodegenerative diseases (Alzheimer's) using precision medicine. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this R&D story with major partners compares to overall economic trends.
